Topic: pharma CEO

The first week of 2019 looks a lot like 2018 in at least one regard: A Big Pharma company’s commercial head is on the move.

Wondering how much incoming Pfizer CEO Albert Bourla is going to shake things up at the drugmaker? Not much, apparently.

With Gilead’s CEO on the way out and revenues tumbling, the company needs a leader who can pump up cancer sales. And it may have found just that.

What does it take for a company to attract millennials? An inspiring culture—and jeans, according to Novartis CEO Vas Narasimhan.

Takeda CEO Christophe Weber and Nissan's now-fallen chairman Carlos Ghosn have much more in common than their French nationality.

FSD Pharma taps competing prescription CBD company GW Pharma’s former top marketing executive to serve as its new CEO.

Pascal Soriot’s reign at AstraZeneca is once again rumored to be coming to an end, and the company has reportedly begun looking for his successor.

There's been no shortage of drug pricing talk in recent weeks, and now Merck's and Pfizer's CEOs have had a chance to voice their thoughts.

Perrigo CEO Uwe Roehrhoff is stepping down effective immediately, the company announced, to be replaced by former tobacco executive Murray Kessler.

Hours after Pfizer unveiled its CEO succession plan, industry watchers had one key question: Will incoming chief Albert Bourla chase M&A?